Filing Details
- Accession Number:
- 0001179110-12-014072
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-09-14 18:19:25
- Reporting Period:
- 2012-09-12
- Filing Date:
- 2012-09-14
- Accepted Time:
- 2012-09-14 18:19:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1034842 | Rigel Pharmaceuticals Inc | RIGL | Pharmaceutical Preparations (2834) | 943248524 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1363984 | D Ryan Maynard | Rigel Pharmaceuticals, Inc. 1180 Veterans Blvd. South San Francisco CA 94080 | Evp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-09-07 | 23,302 | $6.49 | 23,302 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-09-07 | 23,302 | $10.67 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2012-09-12 | 23,302 | $0.00 | 23,302 | $6.49 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
73,300 | 2019-03-30 | No | 4 | M | Direct |
Footnotes
- The shares vest monthly over one(1) year from 3/30/09.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $10.845, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or Securities and Exchange Commission, full information regarding the shares sold at each separate price within the range set forth in footnote (2) of this Form 4.